Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis

Table 3 Surface under the cumulative ranking curve (SUCRA) data for six outcomes

Treatment	Surface Under the Cumulative Ranking Curve (SUCRA)
Treatment	MMR within 12 months	CCyR within 12 months	Progression to AP-CML	Overall Discontinuation	Discontinuation for Drug-related AEs	Serious AEs
Bosutinib 400 mg qd	0.428	0.684	0.259	0.318	0.346	0.572
Bosutinib 500 mg qd	0.570	0.416	0.872	0.520	0.719	0.581
Dasatinib 100 mg qd	0.624	0.736	0.302	0.337	0.312	0.632
IFN + Ara-C	0.000	0.000	0.719	0.726	0.476	–
Imatinib 400 mg qd	0.209	0.335	0.406	0.383	0.158	0.481
Imatinib 400 mg qd + Ara-C	0.172	0.340	0.482	0.903	0.769	0.483
Imatinib 400 mg qd + IFN	0.321	0.411	0.350	0.653	0.958	0.488
Imatinib 400 mg qd after IFN	0.071	0.076	–	–	–	0.159
Imatinib 600 mg qd	0.449	0.311	0.254	0.352	0.187	0.477
Imatinib 800 mg qd	0.682	0.730	0.388	0.525	0.576	0.528
Nilotinib 300 mg bid	0.791	0.759	0.301	0.372	0.234	0.543
Nilotinib 400 mg bid	0.839	0.781	0.293	0.416	0.440	0.556
Ponatinib 45 mg qd	0.997	–	0.419	0.649	0.837	–
Radotinib 300 mg bid	0.750	0.895	–	0.283	0.343	–
Radotinib 400 mg bid	0.596	0.538	–	0.561	0.688	–

ISSN: 1471-2407